I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Roche and Genentech at

Retina Society 2023

October 11 - October 14

New York, USA

www.retinasociety

Medical Materials

Agenda

Coming soon

02:47 PM

Duration 4mins InterContinental New York Barclay - Grand Ballroom

Clinical Outcomes of Diabetic Macular Edema Patients Treated with Faricimab▼ and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across Faricimab▼ Phase 3 Clinical Trials

Holekamp N, Zarbin M, Ding A, Lu X, Ahmed A, Yang M, Evolo V, Stoilov I, Amador M

Ophthalmology | Diabetic Macular Edema

02:53 PM

Duration 5mins InterContinental New York Barclay - Grand Ballroom

Faricimab▼ Treat-and-Extend–based Dosing Dynamics in the Phase 3 YOSEMITE/RHINE Trials

Yonekawa Y, Figueroa M, Pearce I, Lim J, Gibson K, Jain N, Shildkrot E, Souverain A, Yang M, Willis J, Haskova Z

Ophthalmology | Diabetic Macular Edema

02:58 PM

Duration 3mins InterContinental New York Barclay - Grand Ballroom

Time to Retinal Fluid Control With Faricimab▼ vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials

Finn A, Walter S, Lanzetta P, Rachitskaya A, Camino A, Gibson K, Mar F, Shildkrot E, Tang Y, Willis J, Haskova Z

Ophthalmology | Diabetic Macular Edema

03:01 PM

Duration 5mins InterContinental New York Barclay - Grand Ballroom

Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema

Eichenbaum D, Sivaprasad S, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Shildkrot E, Amador M, Mar F, Goldberg R, Camino A

Ophthalmology | Diabetic Macular Edema

03:18 PM

Duration 5mins InterContinental New York Barclay - Grand Ballroom

Efficacy and Safety of Faricimab▼ in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME

Fawzi A, Mar F, Amador M, Glittenberg C, Gibson K, Kotak A, Souverain A

Ophthalmology | Diabetic Macular Edema

03:25 PM

Duration 5mins InterContinental New York Barclay - Grand Ballroom

Early Treatment Patterns and Outcomes in DME Patients Initiating Faricimab▼ in the US and UK

Borkar D, Tabano D, Garmo V, Leng T, Myers R, Laprise A, Singh R, Talks J, Peto T, Dayal P,

Ophthalmology | Diabetic Macular Edema

08:09 AM

Duration 5mins InterContinental New York Barclay - Grand Ballroom

Individualised faricimab▼ dosing increased the proportion of patients with nAMD on Q16W dosing in year 2 of TENAYA/LUCERNE, while maintaining functional and anatomical outcomes

Engelbert M, Sorenson J, Ambresin A, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P, Chaudhary V

Ophthalmology | Neovascular Age Related Macular Degeneration

08:16 AM

Duration 4mins InterContinental New York Barclay - Grand Ballroom

Predictors of Outcomes at Year 1 in Patients Treated With Faricimab in TENAYA/LUCERNE

Kim J, Stoilov I, Yang M, Hill L

Ophthalmology | Neovascular Age Related Macular Degeneration

08:23 AM

Duration 6mins InterContinental New York Barclay - Grand Ballroom

Greater Reduction in Pigment Epithelial Detachment Size With Faricimab▼ vs Aflibercept During Head-to-Head Dosing in Patients With nAMD

Lim J, Margaron P, Souverain A, Yang M, Shildkrot E, Kotecha A, Willis J, Patel S, Khanani A, Bakri S

Ophthalmology | Neovascular Age Related Macular Degeneration

08:35 AM

Duration 3mins InterContinental New York Barclay - Grand Ballroom

Early Treatment Patterns and Outcomes in nAMD Patients Initiating Faricimab▼ in the US and UK

Leng T, Tabano D, Garmo V, Borkar D, Myers R, Laprise A, Singh R, Talks J, Peto T, Dayal P

Ophthalmology | Neovascular Age Related Macular Degeneration

10:49 AM

Duration 7mins InterContinental New York Barclay - Grand Ballroom

Port Delivery System With Ranibizumab (PDS) in Diabetic Macular Edema (DME): Primary Analysis Results of the Phase 3 Pagoda Trial

Klufas M, Marcus D, Graff J, Campochiaro P, Rahman S, Malhotra V, Latkany P, Gune S, DeGraaf S, Cavichini-Cordeiro M, Bobbala A, Rabena M, Quezada-Ruiz C, Khanani A

Ophthalmology | Diabetic Retinopathy - Diabetic Macular Edema

10:56 AM

Duration 7mins InterContinental New York Barclay - Grand Ballroom

Port Delivery System With Ranibizumab (PDS) in Patients With Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME): Primary Analysis Results of the Phase 3 Pavilion Trial

Regillo C, Wykoff C, Chang M, Emanuelli A, Holekamp N, Latkany P, Malhotra V, Brittain C, Howard D, Cavichini-Cordeiro M, Santhanakrishnan A, Wetzel-Smith M,

Ophthalmology | Diabetic Retinopathy - Diabetic Macular Edema

11:09 AM

Duration 4mins InterContinental New York Barclay - Grand Ballroom

Pharmacokinetic (PK) Profile of the Port Delivery System With Ranibizumab (PDS) in the Phase 3 Pagoda and Pavilion Trials

Wolfe J, Dhoot D, Ding HT, Hyung S, Latkany P, Maass K, Rahman S, Hsu J

Ophthalmology | Diabetic Retinopathy - Diabetic Macular Edema

03:30 PM

Duration 3mins InterContinental New York Barclay - Grand Ballroom

Regional Variance in the Enrollment of Underrepresented Patients in US Clinical Trials of DME

Khan MA, Blotner S, Hill L, Amador M, Haller J

Ophthalmology | Diabetic Retinopathy - Diabetic Macular Edema